Astrazeneca Ab

Hans Lönn

Peter Hansen

Antonios Nikitidis

Karolina Lawitz

Asim Ray

Marianne Ivarsson

Matti Juhani Lepistö

Magnus Munck Af Rosenschöld

Michael Lundkvist

Tomas Eriksson

Svetlana Ivanova

John Pavey

Per Tomas Klingstedt

Lars-Erik Briggner

Martin Lindsjö

Andrew James Watts

Debra Ainge

David Chapman

Robert Zuban

Marie-Lyne Alcaraz

Robert Anthony Nixon

Marjana Andersson

Petter Sjölin

Matti Lepistö

There are provided novel compounds of formula (I), wherein R, R, R, G, G, L, Y and n are as defined in the Specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of neutrophil elastase.

2-pyridone derivatives as neutrophil elastase inhibitors and their use

The invention provides certain novel compounds as listed in the specification and pharmaceutically acceptable salts thereof and particular Forms thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase. The present neutrophil elastase inhibitors include 6-[1-(4-Cyanophenyl)-1H-pyrazol-5-yl]-5-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrazine-2-carboxamide: 

Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase

The invention provides compounds of formula wherein R, R, R, R, R, X and W are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.

2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial

6-Methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-{[5-(methylsulfonyl)pyridin-2-yl]methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 4-methylbenzenesulfonate and a novel crystalline form thereof are disclosed together with processes for preparing such salt and form, pharmaceutical compositions comprising such a salt and form, and the methods of treatment using such a salt and form.

Salt 628

There are provided novel compounds of formula (I), wherein R, R, R, R, G, G, L, Y and n are as defined in the Specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of neutrophil elastase. 

The invention provides compounds of formula wherein R, R, R, R, R, R, X and W are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.

2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial

The invention provides compounds of general formula (I) wherein A, X, m, R, N, R, Z, Z, Q, R, R, R, R, R, R, t and Rare as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy 

Benzimidazol derivatives modulate chemokine receptors

Growing community of inventors

Lund, Sweden

Hans Lönn